Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,000 across all filing types
Latest filing 2026-03-27 Proxy Solicitation & In…
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
UCB SA_Convening Notice AGM 2026_FR - FINAL.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal convocation (“convocation à l’assemblée générale des actionnaires”) containing the meeting notice, detailed agenda items, proposed resolutions, voting procedures, proxy instructions (use of Lumi Connect), and supporting information for shareholder decision‐making. This is not the AGM slide presentation itself (AGM-R) nor the executed meeting minutes or voting results (DVA). Instead, it corresponds to materials sent to shareholders to provide information and solicit votes for an upcoming general meeting. Therefore, it best fits the definition of a Proxy Solicitation & Information Statement (PSI).
2026-03-27 French
UCB SA_Convening notice AGM 2026_NL - FINAL.pdf
AGM Information Classification · 1% confidence The document is a formal invitation (“Oproeping tot de Algemene Vergadering van Aandeelhouders”) setting out the agenda and resolutions for the annual and extraordinary general meeting, including approval of the annual accounts, remuneration report, discharge of directors, renewal of board mandates, and capital authorisations. It is not the annual report itself but the meeting materials. This corresponds to AGM Information (Code: AGM-R).
2026-03-27 Dutch
PR11032026.pdf
Regulatory Filings Classification · 1% confidence The document is a press release from UCB announcing positive topline clinical trial data (BE BOLD trial) for their drug BIMZELX. It details the study results, primary endpoints, and safety information. This type of announcement regarding clinical trial outcomes is a standard regulatory disclosure for biopharmaceutical companies, which falls under the 'Regulatory Filings' (RNS) category as it does not fit into specific financial reporting categories like 10-K, ER, or IR.
2026-03-11 English
iar_2025-finalweb.pdf
Annual Report Classification · 1% confidence The document is titled 'Integrated Annual Report 2025' for UCB. It contains comprehensive sections including a strategic report, letter to stakeholders, sustainability statement, corporate governance statement, and financial statements. It is clearly the full annual report for the fiscal year 2025, not an announcement or a summary. FY 2025
2026-02-26 English
ucb-2025-12-31-1-en.xhtml
Annual Report Classification · 1% confidence The document is titled 'Integrated Annual Report 2025' and explicitly states it includes the management report, sustainability statement, corporate governance statement, and financial statements. It covers the full fiscal year 2025 and provides comprehensive financial and operational performance data. It is clearly the company's primary annual reporting document. FY 2025
2026-02-26 English
2138008J191VLSGY5A09-2025-12-31-1-en.xbri
Annual Report Classification · 1% confidence The document is titled 'Integrated Annual Report 2025' and explicitly states it includes the management report, sustainability statement, corporate governance statement, and financial statements. It covers the full fiscal year 2025 and provides comprehensive financial and operational performance data. It is clearly the company's primary annual reporting document. FY 2025
2026-02-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.